Table 2 Clinical-pathological aspects, staging and therapy of penile SCC patients and p16INK4a and hrHPV correlation
| Â | p16INK4a* | P-value | hrHPV | P-value | ||
|---|---|---|---|---|---|---|
Negative (%) | Positive (%) | Negative (%) | Positive (%) | |||
hrHPV | ||||||
 Negative | 76 (52.8) | 12 (27.3) | 0.003 | – | – |  |
 Positive | 68 (47.2) | 32 (72.7) |  |  | ||
Staging | ||||||
 pTis + pTa + pT1(a.b) | 50 (29.4) | 16 (32.6) | 0.7138 | 25 (29.1) | 26 (26.5) | 0.4003 |
 pT2 | 69 (40.6) | 17 (34.7) |  | 38 (44.2) | 35 (35.7) |  |
 pT3 | 48 (28.3) | 14 (28.6) |  | 22 (25.6) | 34 (34.7) |  |
 pT4 | 3 (1.7) | 2 (4.1) |  | 1 (1.1) | 3 (3.1) |  |
Lymph Node Metastasis | ||||||
 Negative | 101 (62.3) | 23 (51.1) | 0.1737 | 55 (66.3) | 49 (52.1) | 0.0566 |
 Positive | 61 (37.7) | 22 (48.9) |  | 28 (33.7) | 45 (47.9) |  |
Locoregional Recurrence | ||||||
 Negative | 106 (72.6) | 33 (78.6) | 0.4374 | 57 (76) | 60 (69.8) | 0.3761 |
 Positive | 40 (27.4) | 9 (21.4) |  | 18 (24) | 26 (30.2) |  |
Metastasis | ||||||
 Negative | 123 (84.2) | 34 (80.9) | 0.6122 | 62 (82.7) | 72 (83.7) | 0.8582 |
 Positive | 23 (15.8) | 8 (19.1) |  | 13 (17.3) | 14 (16.3) |  |
PLI | ||||||
 Mild and Moderate | 99 (58.6) | 31 (64.6) | 0.4539 | 49 (58.3) | 58 (59.8) | 0.842 |
 Intense | 70 (41.4) | 17 (35.4) |  | 35 (41.7) | 39 (40.2) |  |
PPI | ||||||
 Mild and Moderate | 157 (92.9) | 48 (100) | 0.0575 | 82 (97.6) | 90 (92.8) | 0.1356 |
 Intense | 12 (7.1) | 0 (0) |  | 2 (2.4) | 7 (7.2) |  |
ILI | ||||||
 Mild and Moderate | 167 (98.8) | 48 (100) | 0.4489 | 83 (98.8) | 96 (99) | 0.9184 |
 Intense | 2 (1.2) | 0 (0) |  | 1 (1.2) | 1 (1) |  |
IPI | ||||||
 Mild and Moderate | 99 (58.6) | 28 (58.3) | 0.9756 | 46 (54.8) | 56 (57.7) | 0.6878 |
 Intense | 70 (41.4) | 20 (41.7) |  | 38 (45.2) | 41 (42.3) |  |
Surgical procedure | ||||||
 Partial amputation | 127 (73) | 37 (74) | 0.1441 | 64 (72.7) | 75 (75) | 0.5434 |
 Total amputation | 29 (16.7) | 4 (8) |  | 16 (18.2) | 13 (13) |  |
 Others | 18 (10.3) | 9 (18) |  | 8 (9.1) | 12 (12) |  |
Chemotherapy | ||||||
 Negative | 115 (76.7) | 29 (65.9) | 0.1514 | 58 (76.3) | 65 (72.2) | 0.5486 |
 Positive | 35 (23.3) | 15 (34.1) |  | 18 (23.7) | 25 (27.8) |  |
Radiotherapy | ||||||
 Negative | 133 (89.3) | 32 (74.4) | 0.0136 | 65 (85.5) | 76 (85.4) | 0.9807 |
 Positive | 16 (10.7) | 11 (25.6) |  | 11 (14.5) | 13 (14.6) |  |
5mC | ||||||
 < 30% | 2 (1.5) | 0 (0) | 0.528 | 1 (1.5) | 0 (0) | 0.4534 |
 > 30–< 60% | 11 (8.5) | 5 (13.2) |  | 6 (9) | 10 (12) |  |
 > 60% | 116 (90) | 33 (86.8) |  | 60 (89.5) | 73 (88) |  |
5hmC | ||||||
 0% | 18 (14.2) | 8 (21.6) | 0.1236 | 14 (21.2) | 11 (13.5) | 0.5893 |
 < 30% | 34 (26.7) | 11 (29.7) |  | 17 (25.8) | 26 (31.7) |  |
 > 30–< 60% | 29 (22.8) | 12 (32.5) |  | 17 (25.8) | 20 (24.4) |  |
 > 60% | 46 (36.2) | 6 (16.2) |  | 18 (27.2) | 25 (30.4) |  |